CDK9 Inhibitor Pipeline Market Report 2022: Insights About 15+ Companies and 15+ Pipeline Drugs – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “CDK9 Inhibitor – Pipeline Insight, 2022” drug pipelines has been added to ResearchAndMarkets.com’s offering.

This “Cyclin-Dependent Kinase 9 (CDK9) Inhibitor – Pipeline Insight, 2022” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Cyclin-Dependent Kinase 9 (CDK9) Inhibitor pipeline landscape.

It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Cyclin-Dependent Kinase 9 (CDK9) Inhibitor: Overview

CDK9 is not a typical Cdc2-like kinase. It does not act in cell-cycle regulation processes; rather, it acts in differentiation processes. It is the catalytic subunit of P-TEFb that, in association with Cyclin T, has the ability to phosphorilate the CTD substrate of RNA polymerase II and reach the RNA transcription elongation. There are 2 isoforms of the CDK9 protein: the major 42 kDa CDK9 isoform, and the minor 55 kDa isoform.

Function -CDK9 is not a typical Cdc2-like kinase. It does not act in cell-cycle regulation processes; rather, it acts in differentiation processes. It is the catalytic subunit of P-TEFb that, in association with Cyclin T, has the ability to phosphorilate the CTD substrate of RNA polymerase II and reach the RNA transcription elongation. Although there are other cyclin-dependent kinases that are capable of phosphorilating the CTD, the only one that activates gene expression in a catalyst manner is CDK9.

Cyclin-Dependent Kinase 9 (CDK9) Inhibitors- CDK9 is one of the major Pol II-directed kinases of P-TEFb. A number of small-molecule inhibitors of CDK9 kinase activity directed to the ATP-binding pocket have been developed and tested. A number of natural compounds have been identified as non-selective inhibitors of CDKs. The bis-indoles indirubins were the first human-used compounds to be identified as CDK inhibitors. CDK9 Blockade is A Potential Treatment For Pediatric Soft Tissue Sarcomas.

Cyclin-Dependent Kinase 9 (CDK9) Inhibitor Emerging Drugs Chapters

This segment of the Cyclin-Dependent Kinase 9 (CDK9) Inhibitor report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Cyclin-Dependent Kinase 9 (CDK9) Inhibitor Emerging Drugs

Dinaciclib: Merck & Co

Dinaciclib (SCH 727965) is a small molecule inhibitor of cyclin-dependent kinases. Dinaciclib demonstrates potent and selective inhibition of CDK2, CDK5, CDK1, and CDK9 activity. Dinaciclib inhibits cell cycle progression and proliferation in various tumor cell lines in vitro. Dinaciclib is a product of a drug discovery collaboration between Pharmacopeia (later Ligand Pharmaceuticals) and Schering-Plough (later Merck & Co.). The drug is currently in phase 3 of clinical trials for the treatment of Chronic lymphocytic leukaemia.

KB-0742: Kronos Bio

KB-0742 is a selective, orally bioavailable inhibitor of CDK9, a global regulator of transcription and a critical node in the oncogenic TRN resulting from MYC overexpression. MYC is a well-known transcription factor and cancer driver that is dysregulated in a significant proportion of human cancers, often via genomic copy number gain, or amplification. The drug is currently in phase 1/2 of clinical trials for the treatment of Solid tumours.

Alvocidib: Sumitomo Dainippon Pharma Oncology

Alvocidib is an investigational, intravenously administered, small molecule cyclin-dependent kinase 9 (CDK9) inhibitor. Inhibiting CDK9 is thought to downregulate the transcription of target genes, including myeloid cell leukemia 1 (MCL-1), reducing leukemic blast viability in MCL-1-dependent, hematologic malignancies. The drug is currently in phase 2 of clinical trials for the treatment of acute myeloid leukemia.

Major Players working on Cyclin-Dependent Kinase 9 (CDK9) Inhibitor

There are approx. 15+ key companies which are developing the Cyclin-Dependent Kinase 9 (CDK9) Inhibitor. The companies which have their Cyclin-Dependent Kinase 9 (CDK9) Inhibitor drug candidates in the most advanced stage, i.e. phase III include, Merck & Co.

Key Players

• Merck & Co
• Kronos Bio
• Sumitomo Dainippon Pharma Oncology
• AstraZeneca
• Kino Pharma
• Cyclacel Pharmaceuticals
• Bayer
• MEI Pharma
• Syros Pharmaceuticals
• BioTheryX
• Le Sun Pharmaceuticals
• NeoSome Life Sciences
• Adastra Pharmaceuticals/S*Bio
• Virostatics
• GenFleet Therapeutics
• ASINEX

Key Products

• Dinaciclib
• KB-0742
• Alvocidib
• AZD 4573
• TP 1287
• FIT 039
• BAY 1251152
• Seliciclib
• Fadraciclib
• Voruciclib
• SY 5609
• BTX A51

Research Programme: cancer therapeutics

• NEOS 518
• Zotiraciclib

Research Programme: anticancer therapeutics

Research Programme: cyclin-dependant kinases

• GFH 009

Key Topics Covered:

Introduction

Executive Summary

Cyclin-Dependent Kinase 9 (CDK9) Inhibitor: Overview

• Structure
• Mechanism of Action

Pipeline Therapeutics

• Comparative Analysis

Therapeutic Assessment

• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type

Cyclin-Dependent Kinase 9 (CDK9) Inhibitor – Analytical Perspective

In-depth Commercial Assessment

• Cyclin-Dependent Kinase 9 (CDK9) Inhibitor companies’ collaborations, Licensing, Acquisition -Deal Value Trends

Cyclin-Dependent Kinase 9 (CDK9) Inhibitor Collaboration Deals

• Company-Company Collaborations (Licensing / Partnering) Analysis
• Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

• Comparative Analysis

Dinaciclib: Merck & Co

• Product Description
• Research and Development
• Product Development Activities

Mid Stage Products (Phase II)

• Comparative Analysis

Alvocidib: Sumitomo Dainippon Pharma Oncology

• Product Description
• Research and Development
• Product Development Activities

Early Stage Products (Phase I/II)

• Comparative Analysis

KB-0742: Kronos Bio

• Product Description
• Research and Development
• Product Development Activities

Pre-clinical and Discovery Stage Products

• Comparative Analysis

MRTX-1133: Mirati Therapeutics

• Product Description
• Research and Development
• Product Development Activities

Inactive Products

• Comparative Analysis

Cyclin-Dependent Kinase 9 (CDK9) Inhibitor Key Companies

Cyclin-Dependent Kinase 9 (CDK9) Inhibitor Key Products

Cyclin-Dependent Kinase 9 (CDK9) Inhibitor- Unmet Needs

Cyclin-Dependent Kinase 9 (CDK9) Inhibitor- Market Drivers and Barriers

Cyclin-Dependent Kinase 9 (CDK9) Inhibitor- Future Perspectives and Conclusion

Cyclin-Dependent Kinase 9 (CDK9) Inhibitor Analyst Views

Cyclin-Dependent Kinase 9 (CDK9) Inhibitor Key Companies

Appendix

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/1kezbr

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900